Ophthalmic Solutions - Adverse effects
Research News and Information

Sunday, November 22, 2009

Use of eye shields and eye lubricants among oculoplastic and Mohs surgeons: a survey.

30 Aug 2009 BACKGROUND: Eye shields and lubricants are recommended for use in the eye during periorbital surgery to prevent injury to the globe. Nonetheless, data regarding their use is sparse, and no study to date has examined the prevalence of their usage and ... Read more...

GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.

27 Jul 2009 PURPOSE: Pathologic corneal neovascularization not only reduces corneal transparency and visual acuity, but also is one of the most significant preoperative and postoperative risk factors for graft rejection after corneal transplantation. The aim of ... Read more...

Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.

27 Jul 2009 OBJECTIVE: To compare the clinical and antimicrobial efficacy of besifloxacin ophthalmic suspension 0.6% with that of moxifloxacin ophthalmic solution 0.5% for the treatment of bacterial conjunctivitis. DESIGN: Multicenter, randomized, ... Read more...

Latest indexed articles for 'Ophthalmic Solutions - Adverse effects'

These are the very latest articles for this heading:

• Use of eye shields and eye lubricants among oculoplastic and Mohs surgeons: a survey. 30 Aug 2009
• Nepafenac: new drug. After cataract surgery: just another NSAID eye drop. No better than other NSAID eye drops, and less convenient to use. 30 Jul 2009
• GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. 27 Jul 2009
• Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis. 27 Jul 2009
• Evaluation of the cytotoxic effects of ophthalmic solutions containing benzalkonium chloride on corneal epithelium using an organotypic 3-D model. 26 Jul 2009
• Anaphylaxis with use of eye-drops containing benzalkonium chloride preservative. 20 Jun 2009
• Topical administration of chloramphenicol can induce acute hepatitis. 10 Jun 2009
• Latisse: empirical discovery yields treatment for sparse eyelashes. 30 May 2009
• [Pollen allergy and pregnancy. A literature review of anti-allergic agents shows no increased risk of fetal injuries] 30 May 2009
• Mydriatic eye drops: severe adverse effects in children. Systemic reactions. 30 May 2009
• Evaluation of risk of falls and orthostatic hypotension in older, long-term topical beta-blocker users. 17 May 2009
• [Topical inhibition of angiogenesis at the cornea. Safety and efficacy] 29 Apr 2009
• Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. 29 Apr 2009
• Comparison of two artificial tear formulations using aberrometry. 29 Apr 2009
• Clinical efficacy of a Ginkgo biloba extract in the topical treatment of allergic conjunctivitis. 29 Apr 2009
• Effects of some ophthalmic medications on pupil size: a literature review. 30 Mar 2009
• Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. 30 Mar 2009
• The effects of intravitreal ophthalmic medications on intraocular pressure. 27 Feb 2009
• Residual amounts of ophthalmic viscosurgical devices on the corneal endothelium following phacoemulsification. 28 Jan 2009
• [Contact allergy to topical ophthalmological drugs - epidemiological risk assessment] 25 Jan 2009

See a longer list of these articles.

Technical information about 'Ophthalmic Solutions'

Definition: Sterile solutions, essentially free from foreign particles and suitably compounded and dispensed, for instillation into the eye. It does not include solutions for cleaning eyeglasses or CONTACT LENS SOLUTIONS. (From Dorland, 27th ed)

Registry Number: 0

Descriptor UI: D009883

Alternative terms: Ophthalmic Solutions; Solutions, Ophthalmic; Eyedrops; Eye Drops; Drops, Eye; Tears, Artificial; Artificial Tears;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; chemical synthesis; classification; diagnostic use; economics; history; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; chemistry; contraindications;

Tree Number: D26.255.775.645; D26.776.708.645; D27.720.280.775.645;

Online Note: use OPHTHALMIC SOLUTIONS to search SOLUTIONS, OPHTHALMIC 1966

History Note: 67; was SOLUTIONS, OPHTHALMIC 1963-66

Technical Notes: sterile solutions for instillation into the eyes: not for solutions for cleaning eyeglass lenses ( = SOLUTIONS + specific type of lens); not for cleaning contact lenses ( = CONTACT LENS SOLUTIONS); D25-26 qualif if IM & GEN; NIM coord with no qualif + specific drug IM; DF: OPHTHALMIC SOL